Skip to content

Dianthus Therapeutics DNTH Operating Lease Right-of-Use Assets in Other Assets

Operating Lease Right-of-Use Assets in Other Assets at other companies

Kymera Therapeutics logo
Kymera TherapeuticsKYMR
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
TG Therapeutics logo
TG TherapeuticsTGTX
Biogen logo
BiogenBIIB
BridgeBio Pharma logo
BridgeBio PharmaBBIO
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$4.51B+662%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's operating lease right-of-use assets in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dianthus Therapeutics's operating lease right-of-use assets in other assets?
Dianthus Therapeutics (DNTH) reported operating lease right-of-use assets in other assets of $1.29M in Q1 2026.
How has Dianthus Therapeutics's operating lease right-of-use assets in other assets changed year-over-year?
Dianthus Therapeutics's operating lease right-of-use assets in other assets decreased by 10.6% year-over-year, from $1.45M to $1.29M.